FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * MCNAY JOSEPH C 2. Issuer Name and Ticker or Trading Symbol REGENERX BIOPHARMACEUTICALS INC [ RGRX ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
C/O REGENERX BIOPHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 470
3. Date of Earliest Transaction (MM/DD/YYYY)
6/10/2020
(Street)
ROCKVILLE, MD 20850
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock                 6524122  D 
 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)  $.21                   (1) 3/25/2021  Common Stock  120000    120000  D 
 
Stock Option (right to buy)  $.19                   (1) 2/11/2022  Common Stock  100000    100000  D 
 
Stock Option (right to buy)  $.36                   (1) 6/30/2022  Common Stock  100000    100000  D 
 
Stock Option (right to buy)  $.64                   (1) 3/16/2023  Common Stock  100000    100000  D 
 
Stock Option (right to buy)  $.28                   (2) 9/1/2027  Common Stock  125000    125000  D 
 
Stock Option (right to buy)  $.21                   (3) 7/17/2028  Common Stock  200000    200000  D 
 
Stock Option (right to buy)  $.21                   (4) 5/15/2029  Common Stock  250000    250000  D 
 
Stock Option (right to buy)  $.30  6/10/2020    A     250000       (5) 6/10/2030  Common Stock  250000  $0  250000  D 
 
Convertible Promissory Note (right to buy)  $.12                  2/27/2019  2/27/2024  Common Stock  104167    $12500.00  D 
 
Convertible Promissory Note (right to buy)  $.12                  5/13/2019  5/13/2024  Common Stock  104167    $12500.00  D 
 
Common Stock Warrant (right to buy)  $.18                  8/27/2019  2/27/2024  Common Stock  78125    78125  D 
 
Common Stock Warrant (right to buy)  $.18                  11/13/2019  5/13/2024  Common Stock  78125    78125  D 
 

Explanation of Responses:
(1)  100% vested.
(2)  31,250 shares vest on each of 9/1/17, 9/1/18, 9/1/19 and 9/1/20.
(3)  50,000 shares vest on each of 7/17/18, 7/17/19, 7/17/20 and 7/17/21.
(4)  62,500 shares vest on each of 5/15/19, 5/15/20, 5/15/21 and 5/15/22.
(5)  62,500 shares vest on each of 6/10/20, 6/10/21, 6/10/22 and 6/10/23.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
MCNAY JOSEPH C
C/O REGENERX BIOPHARMACEUTICALS, INC.
15245 SHADY GROVE ROAD, SUITE 470
ROCKVILLE, MD 20850
X



Signatures
/s/ Andrew Nick as Attorney-in-Fact for Joseph C. McNay pursuant to Power of Attorney previously filed. 6/12/2020
**Signature of Reporting Person Date
RegeneRX Biopharmaceutic... (QB) (USOTC:RGRX)
Historical Stock Chart
From Nov 2020 to Dec 2020 Click Here for more RegeneRX Biopharmaceutic... (QB) Charts.
RegeneRX Biopharmaceutic... (QB) (USOTC:RGRX)
Historical Stock Chart
From Dec 2019 to Dec 2020 Click Here for more RegeneRX Biopharmaceutic... (QB) Charts.